175 related articles for article (PubMed ID: 17682448)
1. [A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia with overactive bladder].
Kosugi S; Ikemoto I; Furuta A; Shimomura T; Kiyota H; Suzuki Y; Kishimoto K; Egaway S; Torii S; Shirai H; Takeuchi H; Abe K
Nihon Hinyokika Gakkai Zasshi; 2007 Jul; 98(5):691-9. PubMed ID: 17682448
[TBL] [Abstract][Full Text] [Related]
2. [A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia].
Hayashi T; Sakai Y; Saito K; Arai G; Hyochi N; Suzuki M; Masuda H; Kawakami S; Okuno T; Kobayashi T; Kageyama Y; Kihara K
Hinyokika Kiyo; 2002 Jan; 48(1):7-11. PubMed ID: 11868386
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
4. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
[TBL] [Abstract][Full Text] [Related]
5. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Garimella PS; Fink HA; Macdonald R; Wilt TJ
Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
[TBL] [Abstract][Full Text] [Related]
6. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
Awa Y; Suzuki H; Hamano S; Okano T; Sakurayama Y; Ohki T; Egoshi K; Ota S; Mori I; Ichikawa T
Int J Urol; 2008 Aug; 15(8):709-15. PubMed ID: 18662175
[TBL] [Abstract][Full Text] [Related]
7. [A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin].
Utsunomiya N; Matsumoto K; Tsunemori H; Muguruma K; Kawakita M; Kamiyama Y; Kanamaru S; Ito N; Tsukazaki H; Shirahase T; Takahashi T
Hinyokika Kiyo; 2016 Jul; 62(7):341-7. PubMed ID: 27569351
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment and prognostic factors of alpha 1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: a pilot study comparing naftopidil and tamsulosin hydrochloride.
Kawachi Y; Sakurai T; Sugimura S; Iwata S; Noto K; Honda S; Maruyama O
Scand J Urol Nephrol; 2010 Feb; 44(1):38-45. PubMed ID: 20095868
[TBL] [Abstract][Full Text] [Related]
9. [A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia].
Hanyu S; Hatano A; Nishiyama T; Obara K; Takahashi K
Hinyokika Kiyo; 2010 Sep; 56(9):489-94. PubMed ID: 20940522
[TBL] [Abstract][Full Text] [Related]
10. Effect of naftopidil on nocturia after failure of tamsulosin.
Oh-oka H
Urology; 2008 Nov; 72(5):1051-5. PubMed ID: 18817955
[TBL] [Abstract][Full Text] [Related]
11. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
[TBL] [Abstract][Full Text] [Related]
12. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
[TBL] [Abstract][Full Text] [Related]
13. [Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms].
Ge JP; Gong J; Ma HQ; Wei W; Shang XJ; Zhang ZY; Xu S; Wang D; Gao JP
Zhonghua Nan Ke Xue; 2008 Oct; 14(10):927-30. PubMed ID: 19157107
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study.
Ikemoto I; Kiyota H; Ohishi Y; Abe K; Goto H; Kishimoto K; Miki K
Int J Urol; 2003 Nov; 10(11):587-94. PubMed ID: 14633083
[TBL] [Abstract][Full Text] [Related]
15. Naftopidil for the treatment of benign prostate hyperplasia: a systematic review.
Castiglione F; Benigni F; Briganti A; Salonia A; Villa L; Nini A; Di Trapani E; Capitanio U; Hedlund P; Montorsi F
Curr Med Res Opin; 2014 Apr; 30(4):719-32. PubMed ID: 24188134
[TBL] [Abstract][Full Text] [Related]
16. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
Matsukawa Y; Funahashi Y; Takai S; Majima T; Ogawa T; Narita H; Kato M; Gotoh M
J Urol; 2017 Feb; 197(2):452-458. PubMed ID: 27615436
[TBL] [Abstract][Full Text] [Related]
18. Influence of Naftopidil on Plasma Monoamine Levels and Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
Kadekawa K; Sugaya K; Mukoyama H; Sakumoto M; Shimabukuro H; Shimabukuro S; Matayoshi Y; Onaga T; Ashitomi K; Nishijima S
Low Urin Tract Symptoms; 2016 May; 8(2):100-5. PubMed ID: 27111621
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study.
Takeda M; Nishizawa O; Gotoh M; Yoshida M; Takahashi S; Masumori N
Urology; 2013 Oct; 82(4):887-93. PubMed ID: 23953605
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder].
Gao ZW; Xin SY; Zhang JG; Ren XQ; Shang YF; Zhang W; Li HB; Xiao F; Shao CS
Zhonghua Nan Ke Xue; 2014 Mar; 20(3):239-43. PubMed ID: 24738461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
